Analyst: Genmab trading will be neutral despite strong growth

The Danish biotech company announced a guidance upgrade after local trading closed Monday, but this had been anticipated by the market and therefore won’t impact its stock price much, says analyst.

Photo: Tuala Hjarnø / Genmab / PR

Although Genmab announced a guidance upgrade on Monday after closing time in Denmark, where the biotech firm is listed, trading of the company’s shares will lean on the general market development, according to Søren Løntoft Hansen, a senior equity analyst at Sydbank.

The guidance upgrade was driven by sales growth of cancer drug Darzalex, which is Genmab’s primary source of revenue, as well as a currency boost from a strong US dollar.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Further reading

Related articles

Latest news

See all jobs